vs
HOME BANCSHARES INC（HOMB）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
HOME BANCSHARES INC的季度营收约是Ultragenyx Pharmaceutical Inc.的1.4倍（$282.1M vs $207.3M），HOME BANCSHARES INC净利率更高（41.9% vs -62.0%，领先103.9%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 9.2%），HOME BANCSHARES INC自由现金流更多（$377.0M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 7.0%）
Home BancShares Inc是以Centennial Bank为运营品牌的银行控股企业，总部位于美国阿肯色州康威市，属于美国大型银行机构，目前在阿肯色、阿拉巴马、佛罗里达、得克萨斯四州及纽约市共设有222家营业网点。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
HOMB vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $282.1M | $207.3M |
| 净利润 | $118.2M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | 54.4% | -54.7% |
| 净利率 | 41.9% | -62.0% |
| 营收同比 | 9.2% | 25.9% |
| 净利润同比 | 17.6% | 3.5% |
| 每股收益（稀释后） | $0.60 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $282.1M | $207.3M | ||
| Q3 25 | $277.7M | $159.9M | ||
| Q2 25 | $271.0M | $166.5M | ||
| Q1 25 | $260.1M | $139.3M | ||
| Q4 24 | $258.4M | $164.6M | ||
| Q3 24 | $258.0M | $139.5M | ||
| Q2 24 | $254.6M | $147.0M | ||
| Q1 24 | $246.4M | $108.8M |
| Q4 25 | $118.2M | $-128.6M | ||
| Q3 25 | $123.6M | $-180.4M | ||
| Q2 25 | $118.4M | $-115.0M | ||
| Q1 25 | $115.2M | $-151.1M | ||
| Q4 24 | $100.6M | $-133.2M | ||
| Q3 24 | $100.0M | $-133.5M | ||
| Q2 24 | $101.5M | $-131.6M | ||
| Q1 24 | $100.1M | $-170.7M |
| Q4 25 | 54.4% | -54.7% | ||
| Q3 25 | 57.4% | -106.9% | ||
| Q2 25 | 56.1% | -64.8% | ||
| Q1 25 | 56.6% | -102.6% | ||
| Q4 24 | 50.1% | -74.3% | ||
| Q3 24 | 50.0% | -94.6% | ||
| Q2 24 | 52.4% | -79.1% | ||
| Q1 24 | 52.9% | -151.9% |
| Q4 25 | 41.9% | -62.0% | ||
| Q3 25 | 44.5% | -112.8% | ||
| Q2 25 | 43.7% | -69.0% | ||
| Q1 25 | 44.3% | -108.5% | ||
| Q4 24 | 38.9% | -80.9% | ||
| Q3 24 | 38.8% | -95.7% | ||
| Q2 24 | 39.9% | -89.5% | ||
| Q1 24 | 40.6% | -156.8% |
| Q4 25 | $0.60 | $-1.28 | ||
| Q3 25 | $0.63 | $-1.81 | ||
| Q2 25 | $0.60 | $-1.17 | ||
| Q1 25 | $0.58 | $-1.57 | ||
| Q4 24 | $0.50 | $-1.34 | ||
| Q3 24 | $0.50 | $-1.40 | ||
| Q2 24 | $0.51 | $-1.52 | ||
| Q1 24 | $0.50 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $667.3M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $4.3B | $-80.0M |
| 总资产 | $22.9B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $667.3M | $421.0M | ||
| Q3 25 | $800.9M | $202.5M | ||
| Q2 25 | $1.1B | $176.3M | ||
| Q1 25 | $1.3B | $127.1M | ||
| Q4 24 | $910.3M | $174.0M | ||
| Q3 24 | $1.0B | $150.6M | ||
| Q2 24 | $1.1B | $480.7M | ||
| Q1 24 | $1.2B | $112.3M |
| Q4 25 | $4.3B | $-80.0M | ||
| Q3 25 | $4.2B | $9.2M | ||
| Q2 25 | $4.1B | $151.3M | ||
| Q1 25 | $4.0B | $144.2M | ||
| Q4 24 | $4.0B | $255.0M | ||
| Q3 24 | $4.0B | $346.8M | ||
| Q2 24 | $3.9B | $432.4M | ||
| Q1 24 | $3.8B | $140.3M |
| Q4 25 | $22.9B | $1.5B | ||
| Q3 25 | $22.7B | $1.2B | ||
| Q2 25 | $22.9B | $1.3B | ||
| Q1 25 | $23.0B | $1.3B | ||
| Q4 24 | $22.5B | $1.5B | ||
| Q3 24 | $22.8B | $1.5B | ||
| Q2 24 | $22.9B | $1.6B | ||
| Q1 24 | $22.8B | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $399.3M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $377.0M | $-100.8M |
| 自由现金流率自由现金流/营收 | 133.7% | -48.6% |
| 资本支出强度资本支出/营收 | 7.9% | 0.5% |
| 现金转化率经营现金流/净利润 | 3.38× | — |
| 过去12个月自由现金流最近4个季度 | $669.8M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $399.3M | $-99.8M | ||
| Q3 25 | $115.2M | $-91.4M | ||
| Q2 25 | $78.4M | $-108.3M | ||
| Q1 25 | $117.0M | $-166.5M | ||
| Q4 24 | $460.6M | $-79.3M | ||
| Q3 24 | $128.6M | $-67.0M | ||
| Q2 24 | $109.4M | $-77.0M | ||
| Q1 24 | $147.5M | $-190.7M |
| Q4 25 | $377.0M | $-100.8M | ||
| Q3 25 | $112.2M | $-92.7M | ||
| Q2 25 | $70.4M | $-110.7M | ||
| Q1 25 | $110.1M | $-167.8M | ||
| Q4 24 | $422.1M | $-79.5M | ||
| Q3 24 | $116.2M | $-68.6M | ||
| Q2 24 | $99.2M | $-79.0M | ||
| Q1 24 | $145.9M | $-193.9M |
| Q4 25 | 133.7% | -48.6% | ||
| Q3 25 | 40.4% | -58.0% | ||
| Q2 25 | 26.0% | -66.5% | ||
| Q1 25 | 42.3% | -120.5% | ||
| Q4 24 | 163.4% | -48.3% | ||
| Q3 24 | 45.1% | -49.2% | ||
| Q2 24 | 38.9% | -53.7% | ||
| Q1 24 | 59.2% | -178.2% |
| Q4 25 | 7.9% | 0.5% | ||
| Q3 25 | 1.0% | 0.8% | ||
| Q2 25 | 3.0% | 1.5% | ||
| Q1 25 | 2.6% | 1.0% | ||
| Q4 24 | 14.9% | 0.1% | ||
| Q3 24 | 4.8% | 1.2% | ||
| Q2 24 | 4.0% | 1.4% | ||
| Q1 24 | 0.7% | 3.0% |
| Q4 25 | 3.38× | — | ||
| Q3 25 | 0.93× | — | ||
| Q2 25 | 0.66× | — | ||
| Q1 25 | 1.02× | — | ||
| Q4 24 | 4.58× | — | ||
| Q3 24 | 1.29× | — | ||
| Q2 24 | 1.08× | — | ||
| Q1 24 | 1.47× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HOMB
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
